🔗 Share this article World Health Organization Issues Warning Over Acute Shortage of Obesity Injections Under a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy can access them, warns the global health agency as it releases its first recommendations on the medications. Considering more than one billion individuals worldwide now obese, it is calling for broader and more equitable availability to this class of drugs. According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention. "The new guidelines recognises that obesity is a long-term condition that can be managed with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and logistical bottlenecks are major obstacles to widespread access to the injections that can aid individuals in losing significant body mass, explains the agency. GLP-1 Therapy Shortage Even in the present best projected case, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The advice calls on nations and manufacturers to increase access, via approaches like patent sharing. The intellectual property rights on a key compound – the main ingredient of a leading brand – is due to expire in a number of countries in 2026. The Way Obesity Injections Operate The injections mimick a natural hormone to reduce digestion speed, curb appetite and enhance satiety so users eat less. Individuals commonly start to lose weight within a few weeks of beginning the regular doses. Research indicates patients may regain a significant portion after a year of stopping the drug, because their normal appetite return. To be carrying excess weight raises your likelihood for developing diseases, including diabetes, cardiovascular issues, brain attack, and some cancers. Excess weight impacts people in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
Under a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy can access them, warns the global health agency as it releases its first recommendations on the medications. Considering more than one billion individuals worldwide now obese, it is calling for broader and more equitable availability to this class of drugs. According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention. "The new guidelines recognises that obesity is a long-term condition that can be managed with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and logistical bottlenecks are major obstacles to widespread access to the injections that can aid individuals in losing significant body mass, explains the agency. GLP-1 Therapy Shortage Even in the present best projected case, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The advice calls on nations and manufacturers to increase access, via approaches like patent sharing. The intellectual property rights on a key compound – the main ingredient of a leading brand – is due to expire in a number of countries in 2026. The Way Obesity Injections Operate The injections mimick a natural hormone to reduce digestion speed, curb appetite and enhance satiety so users eat less. Individuals commonly start to lose weight within a few weeks of beginning the regular doses. Research indicates patients may regain a significant portion after a year of stopping the drug, because their normal appetite return. To be carrying excess weight raises your likelihood for developing diseases, including diabetes, cardiovascular issues, brain attack, and some cancers. Excess weight impacts people in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.